LifeSci Capital Initiates Coverage of Can-Fite BioPharma

Companies Mentioned:

Primary Exchange: AMEX
Under the Symbol: CANF

LifeSci Capital Initiates Coverage of Can-Fite BioPharma

Monday, April 11, 2016 5:13 PM

Biopharmaceutical Company Developing Treatments for Cancer, Inflammatory Diseases, and Sexual Dysfunction; Report Available here: http://www.lifescicapital.com/equity-research/can-fite/

NEW YORK, NY / ACCESSWIRE / April 11, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Can-Fite BioPharma (NYSE MKT: CANF), a clinical stage biopharmaceutical company developing therapeutics for cancer, inflammatory diseases, and sexual dysfunction. The Company's product candidates are based on a validated and proprietary technology platform that involves the A3 adenosine G protein-coupled receptor (A3AR), which is highly expressed on inflammatory and cancer cells.

Can-Fite's lead product candidate CF101, an orally bioavailable A3AR agonist for the treatment of rheumatoid arthritis (RA) and psoriasis, has demonstrated efficacy in clinical trials and is poised to enter Phase III trials in the second half of 2016. RA is a chronic, systemic autoimmune disorder that affects more than 1.5 million patients in the US, and 2.9 million around the world. It is estimated that approximately 70% of these patients would present with A3AR-postive disease and thus be suitable candidates for CF101 therapy. Results from a randomized Phase II trial demonstrated that 48.6% of CF101-treated subjects achieved a 20% reduction in RA disease activity compared to 25% in the placebo group (p=0.035). CF101 is being developed as a more convenient and better-tolerated alternative to injectable systemic RA therapies. Can-Fite expects to initiate a Phase III trial with CF101 in RA in the third quarter of 2016. The Company also intends to initiate a Phase III trial in plaque psoriasis in the fourth quarter of 2016.

Can-Fite's product candidate for liver cancer and NASH is CF102, a second-generation A3AR agonist that reduces inflammation and inhibits tumor cell growth. The Company is currently conducting a Phase II trial for CF102 in patients with hepatocellular carcinoma and plans to initiate a Phase II study in NASH by the end of the year. The Company also plans to initiate a Phase I study with its allosteric A3AR regulator CF602 in erectile dysfunction in 2016.

In a 40 page Initiation Report LifeSci Capital explains the need for safe and convenient RA and psoriasis therapies, as well as the unmet medical need in liver cancer, NASH, and erectile dysfunction. The report also discusses the MOA of CF101, CF102 and CF602, and the large market opportunities

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Can-Fite as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: [email protected]

SOURCE: LifeSci Capital, LLC


Subscribe to alerts from Investor Network
SHARE ARTICLE